Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 5/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988717 | 0.88 | CXCR4 (0.44) | CXCR4 | |
| Trifluoroacetic Acid SCHEMBL2418668 | 0.86 | TP53 (0.40) | HRH4HRH3CXCR4 | |
| Iodide SCHEMBL2419341 | 0.79 | CXCR4 (0.49) | CXCR4 | |
| Trifluoroacetic Acid SCHEMBL31657036 | 0.65 | MEN1 (0.52) | HRH4HRH3CPB2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL31657055 | 0.65 | MEN1 (0.52) | HRH4HRH3CPB2HDAC6 | |
| Diaminooctane SCHEMBL31657050 | 0.65 | MEN1 (0.52) | HRH4HRH3CPB2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL29682080 | 0.65 | MEN1 (0.52) | HRH4HRH3CPB2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL6490887 | 0.63 | HRH4 (0.50) | HRH4HRH3CPB2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL31581995 | 0.62 | HDAC6 (0.56) | HDAC6 | |
| Trifluoroacetic Acid SCHEMBL31581884 | 0.62 | HDAC6 (0.56) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012985-B2 | parasiticides, in particularly against Plasmodium and babesia; antimalarial agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20050176819-A1 | Compounds with antiparasitic activity and medicines containing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176819-A1 | Compounds with antiparasitic activity and medicines containing same | ACHE, MPO, PDF | HRH4 1682/4885HRH3 1744/4885CXCR4 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.